WJ47156 / Shanghai Junshi Bioscience, Wigen Biomedicine - LARVOL DELTA

Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=59 | Active, not recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Recruiting ➔ Active, not recruiting | N=93 ➔ 59 | Trial primary completion date: May 2026 ➔ Dec 2026

Enrollment change • Enrollment closed • Monotherapy • Trial primary completion date • Oncology • Solid Tumor

Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=93 | Recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Metastases • Monotherapy • Oncology • Solid Tumor

Junshi Biosciences and Microgene Biotech jointly developed a new type 1 cancer drug approved for clinical trials [Google translation] (HMP Global) - "Today (September 26), the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration announced that WJ47156 tablets applied by Junshi Biosciences have obtained implicit approval for clinical trials and are intended to be developed to treat advanced malignant tumors."

New trial